Serum miR-455-5p and Cardiac Structure and Function Parameters in Patients With Hypertensive Heart Disease
Launched by THE UNIVERSITY OF HONG KONG-SHENZHEN HOSPITAL · Jun 13, 2025
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
The purpose of this study was to collect blood samples of hypertensive patients, in order to clarify the correlation between serum miR-455-5p level and cardiac function. Generally, by using q-PCR assay, miR-455-5p level of each participants will be collected. Besides, SBP, DBP, LVPWd, LVIDd, IVSTd was detected by echocardiography and EF, FS, LVMi, RWT level was further calculated by LVIDd, LVPWd and IVSTd. Finally, the correlation of miR-455-5p level of HHD patients and LVPWd, LVIDd, IVSTd, EF, FS, LVMi, RWT, SBP, DBP was analysed.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. age ≥18 years; 2. male or female; 3. systolic blood pressure ≥140mmHg or (and) diastolic blood pressure \> 90mmHg; 4. history of hypertension\>1year, NYHA grade I-IV
- Exclusion Criteria:
- • hypertensive heart diseases patients with other metabolic diseases or congenital diseases were excluded from the study
About The University Of Hong Kong Shenzhen Hospital
The University of Hong Kong-Shenzhen Hospital (HKU-SZH) is a leading clinical research institution dedicated to advancing healthcare through innovative medical research and trials. Established as a collaboration between the University of Hong Kong and the Shenzhen municipal government, the hospital integrates clinical practice, education, and research, fostering a multidisciplinary approach to patient care. HKU-SZH is committed to enhancing medical knowledge and improving treatment outcomes by conducting rigorous clinical trials across various therapeutic areas. With a focus on ethical standards and patient welfare, the hospital aims to contribute to the global medical community through impactful research and collaboration.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shenzhen, Guangdong, China
Patients applied
Trial Officials
Assistant research fellow
Principal Investigator
The University of Hong Kong-Shenzhen Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported